Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance

About this update from Tandem Diabetes Care, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":221,"url":"https://media.zenfs.com/en/business-wire.com/65b5342a52ab74eb3021531cbb1878d5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/E7sZ4MvkqJhb0iV8F2zVAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/65b5342a52ab74eb3021531cbb1878d5","width":480,"height":221}},"lazy":false},{"type":"text","content":"SAN DIEGO, February 19, 2026--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and fiscal year ended December 31, 2025 and provided its financial guidance for the year ending December 31, 2026.","length":316,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2025 Financial and Strategic Highlights","length":54,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Achieved record quarterly sales:","length":32,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Worldwide sales of $290.4 million","length":33,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"United States sales of $210.5 million","length":37,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Worldwide pump shipments of 38,000","length":34,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"United States pump shipments of 27,000","length":38,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":142,"olType":false}]},{"val":[{"type":"text","content":"Delivered meaningful operational improvement:","length":45,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Record quarterly gross margin of 58%","length":36,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Operating income of $8.3 million, or 3% of sales","length":48,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Net loss of $0.6 million with positive adjusted EBITDA(1) of 11% of sales","length":73,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Positive cash flow from operating activities of $9.8 million and positive free cash flow(1) of $3.1 million","length":107,"tagName":"p","attribs":{}}]}],"tagName"...

More updates from Tandem Diabetes Care, Inc.